P934: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Post Hoc Analysis of Sustained Minimal Residual Disease Negativity From Griffin

Rodríguez, Carlos J.; Kaufman, Jonathan L.; Laubach, Jacob P.; Sborov, Douglas W.; Reeves, Brandi; Chari, Ajai; Silbermann, Rebecca; Costa, Luciano J.; Anderson, L. D.; Nathwani, Nitya; Shah, Neha D.; Bumma, Naresh; Jakubowiak, Andrzej; Orłowski, Robert Z.; Pei, Huiling; Cortoos, A.; Patel, Shefali; Lin, Tai-an; Richardson, PG; Voorhees, Peter M.

doi:10.1097/01.hs9.0000846604.67185.0c

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sustained MRD neg a tiv ity rates were higher in the D-RVd vs RVd groups after 12 months in all rel e vant sub groups, includ ing high-risk patients, asso ci ated with improved PFS for all inten tion-to-treat patients. 13 Estimated 48-month PFS rates were 87.2% for D-RVd and 70.0% for RVd. The phase 3 ran dom ized PERSEUS trial that com pared these same 2 arms and eval u ated if daratumumab can be discontinued in patients with sustained MRD neg a tiv ity is ongo ing.…”

Section: Four-drug Reg I Mensmentioning

confidence: 91%

Newly diagnosed multiple myeloma: making sense of the menu

Costello

2022

Hematology

View full text Add to dashboard Cite

The development of new drugs and subsequent novel combinations for the treatment of newly diagnosed multiple myeloma (NDMM) has resulted in a plethora of treatment options that can make the choice of initial induction therapy a challenge. A greater understanding of both patient- and disease-specific factors can provide a personalized approach to help design a treatment course. Historically, the choice of an induction regimen has been tethered to an initial impression of transplant eligibility at the time of diagnosis. As more effective and better-tolerated induction regimens have emerged, there has been increasing overlap in the induction strategies used for all patients with NDMM, which increasingly provide the ultimate goal of deep and durable remissions. The current treatment options and strategies for the management of NDMM are evaluated using the best available data to provide a rationale for these decisions.

show abstract

Section: Four-drug Reg I Mensmentioning

confidence: 91%

Newly diagnosed multiple myeloma: making sense of the menu

Costello

2022

Hematology

View full text Add to dashboard Cite

show abstract

“…The conclusion from this meta-analysis was that patients with newly diagnosed HRMM may benefit from an altered, more intensive backbone regimen as the first line therapy and advocates for a risk-adjusted guideline for frontline therapy selection. The addition of Daratumumab to frontline induction, consolidation, and maintenance therapies for HRMM has been shown to improve MRD-negativity rates among high-risk patients [102]. The achievement of sustained MRD negativity may be considered a surrogate for longer PFS and OS, regardless of cytogenetic risk [103,104].…”

Section: Car-t In Frontline Therapy For High-risk Patientsmentioning

confidence: 99%

Adoptive Immunotherapy and High-Risk Myeloma

Duane

O’Dwyer

Glavey

2023

Cancers

View full text Add to dashboard Cite

Despite significant improvements in the treatment of multiple myeloma (MM), it remains mostly incurable, highlighting a need for new therapeutic approaches. Patients with high-risk disease characteristics have a particularly poor prognosis and limited response to current frontline therapies. The recent development of immunotherapeutic strategies, particularly T cell-based agents have changed the treatment landscape for patients with relapsed and refractory disease. Adoptive cellular therapies include chimeric antigen receptor (CAR) T cells, which have emerged as a highly promising therapy, particularly for patients with refractory disease. Other adoptive cellular approaches currently in trials include T cell receptor-based therapy (TCR), and the expansion of CAR technology to natural killer (NK) cells. In this review we explore the emerging therapeutic field of adoptive cellular therapy for MM, with a particular focus on the clinical impact of these therapies for patients with high-risk myeloma.

show abstract